💊

Low-Dose Buprenorphine Protocols

Aug 31, 2025

Overview

This episode of the Curbsiders Addiction Medicine podcast discusses low-dose buprenorphine (bup) initiation protocols, particularly rapid 4-day starts for patients with opioid use disorder (OUD), including practical tips, challenges, patient education, and implementation in different clinical settings.

Introduction & Guest Backgrounds

  • Hosts introduce Dr. Carolyn Shan, Dr. Era Kraso, Nurse Practitioner Amelia Goff, and Dr. Alisa Sokolski.
  • Guests work at Oregon Health and Science University in addiction medicine and share backgrounds in infectious disease, psychiatry, internal medicine, and harm reduction clinics.

Fundamentals of Low-Dose Buprenorphine Starts

  • Buprenorphine is a partial opioid agonist with high receptor affinity, risking precipitated withdrawal if started too soon after fentanyl use.
  • Fentanyl’s lipophilicity leads to prolonged retention in tissues, increasing risk of withdrawal with standard bup induction.
  • Patient education with visual aids and analogies (e.g., "Gorilla Glue," "walking down stairs") helps explain precipitated withdrawal and gradual induction.

Low-Dose Buprenorphine Initiation Protocols

  • Traditional induction requires moderate withdrawal and may not suit patients with pain or fentanyl use.
  • Rapid low-dose ("microdosing") protocols allow overlap with full agonist opioids, minimizing withdrawal and accommodating acute pain management.
  • Example 4-day protocol: Day 1—bup patch; Day 2—low sublingual doses; Day 3—increased sublingual doses; Day 4—maintenance dose (up to 24-32 mg).
  • Institutional and regional differences exist in available bup formulations (patch, sublingual, film).

Patient Selection & Clinical Scenarios

  • Low-dose bup starts are especially useful for patients using non-prescribed fentanyl, those with ongoing pain, or those unable to tolerate traditional induction.
  • Not ideal for patients on short-acting opioids or very high-dose methadone, where slower induction may be preferred.
  • Pregnant patients and those needing rapid transition to extended-release formulations benefit from rapid protocols.

Implementation Challenges & Solutions

  • Frequent dosing (e.g., every 3 hours) can be challenging for nursing staff; missed doses may require protocol adjustments.
  • Education for nurses, pharmacists, and providers is critical for successful protocol adoption.
  • Management includes titrating full agonist opioids and using adjunct meds for withdrawal symptoms.

Outpatient Adaptation & Patient Support

  • Outpatient low-dose starts are adapted to available resources; providers cannot prescribe full agonist opioids to manage withdrawal outside the hospital.
  • Detailed patient messaging, written instructions, pill-cutting guidance, and close follow-up (via telemedicine and peer support) help ensure adherence.
  • Bubble packaging by pharmacies can assist but is not widely available.

Patient Feedback & Takeaways

  • Patients report feeling relieved and supported with low-dose protocols as they reduce withdrawal and anxiety.
  • Patient education and shared decision-making are emphasized as building trust and protocol success.
  • Ongoing research on patient experiences is underway.

Professional Community & Resources

  • Importance of professional community support through organizations like the American Society of Addiction Medicine (ASAM) and Echo programs.
  • Encouragement for providers in isolated or resource-limited settings to seek out communities and educational resources to reduce burnout.

Decisions

  • Adopt rapid 4-day low-dose buprenorphine protocol as standard for suitable hospital patients at OHSU.

Action Items

  • TBD – Team: Continue quality improvement and collect feedback for protocol refinement.
  • TBD – Pharmacy/Providers: Develop/expand bubble-packaging options for outpatient low-dose inductions.
  • TBD – Research Team: Conduct qualitative study on patient experiences with low-dose buprenorphine protocols.

Recommendations / Advice

  • Always manage withdrawal, cravings, and pain with adequate full agonist opioids until stable on ≥8 mg buprenorphine.
  • Provide thorough education to all patients and clinical staff before and during induction.
  • Offer patients choices and remain flexible to adjust protocols based on individual needs.